Medicines cure diseases, prevent or delay their progress, shorten their treatment duration and prolong lives in many cases. However, adverse drug effects can also cause reversible or irreversible, sometimes even life-threatening damages. Unfortunately, treatment of those damages is associated with high costs.
The objective of our working group is to ensure best possible safety in drug therapy and in the use of those therapies within inpatient and outpatient care as well as in cross-sectoral areas. The aim is to enhance the patients’ quality of life.
An accurate risk-benefit assessment must therefore be carried out when using medicinal products. Many adverse drug reactions can be prevented by appropriate regulatory and application recommendations. Thus, medical personnel, care and the manufacturing and issuing pharmacy work together in an interdisciplinary collaboration. Hence, errors in medication and drug related problems should be limited or even prevented. Our working group increases patient safety by identifying medication errors. We also connect questions of health care, research (usually healthcare research) and teaching in medical education. Especially, we focus on optimizing drug therapy, dose optimization, risk minimization, individualized drug therapy, clarification of adverse events and pharma economic questions.